Takada M, Fukuoka M, Takifuji N, Sakai N, Ryu S, Masuda N, Matsui K, Negoro S, Kusunoki Y, Tsubura E
2nd Dept. of Internal Medicine, Osaka Prefectural Habikino Hospital.
Gan To Kagaku Ryoho. 1988 Nov;15(11):3095-101.
Muroctasin, a derivative of MDP, is known to augment the number of WBC via colony-stimulating factor. Muroctasin has been expected to be promising for application to leukopenia caused by anticancer chemotherapy. When WBC decreased to less than or equal to 3,000/mm3 after the 1st course of chemotherapy, 131 patients with lung cancer, who were previously classified by chemotherapy combination, were enrolled in the study and randomized into 3 groups, 200 micrograms (H), 100 micrograms (L) and untreated control (C) groups. The patients were then subcutaneously treated once daily for 6 consecutive days. WBC and its differential count were measured on days 4, 7 and 15 after commencement of the study. WBCs in H and L groups showed greater recovery than in C group. In WBC differential count, the recovery of neutrophil was prominent in muroctasin-treated groups. A portion of immature neutrophil in bone marrow was also increased by muroctasin treatment. In the present study, the usefulness of muroctasin in leukopenia was indicated when administered at dosages of 200 micrograms for 6 days.
胞壁酰三肽，一种MDP的衍生物，已知可通过集落刺激因子增加白细胞数量。胞壁酰三肽有望应用于抗癌化疗引起的白细胞减少症。在第一个疗程化疗后白细胞降至小于或等于3000/mm³时，将131例先前按化疗组合分类的肺癌患者纳入研究，并随机分为3组，即200微克（高剂量组，H）、100微克（低剂量组，L）和未治疗对照组（C组）。然后患者连续6天每天皮下注射一次。在研究开始后的第4天、第7天和第15天测量白细胞及其分类计数。高剂量组和低剂量组的白细胞恢复情况比对照组更好。在白细胞分类计数中，胞壁酰三肽治疗组中性粒细胞的恢复尤为显著。胞壁酰三肽治疗还使骨髓中一部分未成熟中性粒细胞增加。在本研究中，当以200微克的剂量给药6天时，表明胞壁酰三肽对白细胞减少症有效。
